oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Bachelor thesis in biotechnology companies: From research to diagnostics
BlogWhat can emerge from basic research? This question followed Lena Bernstein during her studies in Biochemistry and Molecular Biology at the University of Jena. To find answers, she chose to […]
Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%
Press ReleasesPorto / Jena, November 26, 2024 – Methylation tests could significantly increase the accuracy of cervical cancer screening and reduce referrals for colposcopy, which would, in turn, put less strain […]
Methylation Testing for Tumor Detection: A Non-Invasive Alternative to Standard Diagnostics
Press ReleasesJena / Düsseldorf, November 7, 2024 – Molecular biological diagnostics offer a non-invasive alternative for cancer detection. oncgnostics GmbH will demonstrate this in Düsseldorf at MEDICA, one of the world’s […]
Oncgnostics expands international distribution
Press ReleasesJena, July 22 – Oncgnostics GmbH signs an agreement with Seegene Germany GmbH for the international distribution of its own tests. Dr. Alfred Hansel, Managing Director of Oncgnostics: “The agreement […]
Psychological stress in cervical cancer tabood
Press ReleasesMedia study: A recent media study by Oncgnostics GmbH shows that, although the general media report on the topic of cervical cancer, they do not address the associated psychological stress […]
Molecular biological cancer diagnostics close gaps in cancer screening
Press ReleasesTwo tests for cervical cancer with different objectives in cervical cancer screening Liquid biopsy for rapid and gentle diagnosis of head and neck tumours Current studies: GynTect DNA methylation test […]
Hong Kong firm invests in Jena-based Oncgnostics GmbH
Press ReleasesJena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer […]
Harald zur Hausen – in memory of a pioneer of cancer prevention
BlogProf. Dr Harald zur Hausen died on 28 May 2023. With his research, he laid the foundation for a new way of cancer prevention. We at oncgnostics commemorate the internationally […]
World Cancer Day: Saving lives with groundbreaking cancer diagnostics
BlogClose the care gap – that is the slogan of this year’s World Cancer Day on 4th of February. Cancer can be prevented and lives saved through screening. Preventive measures […]
WHO strategy to fight cervical cancer
BlogThe WHO’s cervical cancer strategy has been in place since 2020, when the World Health Organization highlighted that cervical cancer still is the fourth most common cancer in women worldwide. […]